Human IgE monoclonal antibodies to antibodies to alpha-gal (galactose-α-1,3-galactose) and uses therefor
AssigneeVanderbilt University
InventorScott A. Smith
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1, 3-galactose, a known red meat allergen, and methods for use thereof.
Claims23
A method of detecting galactose-α-1,3-galactose (alpha-gal) in a sample comprising:
- (a) contacting a sample with an antibody or antibody fragment comprising (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10 and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively;
- and
- (b) detecting alpha-gal in said sample by binding of said antibody or antibody fragment to alpha-gal in said sample.
A method of detecting IgE anti-galactose-α-1,3-galactose (alpha-gal) antibodies in a sample comprising:
- (a) contacting a sample suspected IgE anti-alpha gal antibodies with alpha-gal in a competitive assay with an antibody or antibody fragment comprising (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10 and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively;
- and
- (b) detecting competition for binding of alpha-gal by a suspected IgE anti-alpha gal in said sample by an antibody or antibody fragment comprising (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10 and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively.
A method of preventing or treating an alpha-gal-related allergic reaction in a subject comprising delivering to said subject an IgG antibody or antibody fragment comprising (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10 and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively.
An IgG monoclonal antibody or antibody fragment thereof, wherein the antibody or antibody fragment comprises (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10, and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively.
An engineered cell encoding an antibody or antibody fragment wherein the antibody or antibody fragment comprises (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10 and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively.
A method of de-sensitizing a subject to galactose-α-1,3-galactose (alpha-gal) comprising:
- (a) administering to said subject galactose-α-1,3-galactose (alpha-gal);
- and
- (b) administering to said subject an IgG antibody that has a binding specificity to galactose-α-1,3-galactose (alpha-gal) fragment and comprising (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10 and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively.
A monoclonal antibody or antibody fragment thereof comprising (i) heavy chain CDR1-3 comprising SEQ ID NOS:
- 9, 10, and 11, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 15, 16 and 17, respectively, or (ii) heavy chain CDR1-3 comprising SEQ ID NOS:
- 12, 13 and 14, respectively, and light chain CDR1-3 comprising SEQ ID NOS:
- 18, 19 and 20, respectively, wherein the antibody or antibody fragment comprises an Fc portion mutated to alter FcR interactions, to increase half-life and/or increase therapeutic efficacy or is glycan modified to alter FcR interactions.
Dependencies are inferred from the claim text.